Management ChangeMay 19, 2026, 08:16 AM
Artiva Biotherapeutics Appoints New President R&D; CFO Departs
AI Summary
Artiva Biotherapeutics announced several leadership changes, including the departure of its Chief Financial Officer, Thad Huston, effective May 22, 2026. Concurrently, Dr. Diego Miralles resigned from the Board to assume the role of President and Head of Research and Development. Dr. Fred Aslan, who resigned as President, will continue as CEO and Board member, and has been appointed principal financial and accounting officer. Mr. Huston will receive a severance package including a $135,000 cash payment and COBRA benefits, while Dr. Miralles's new compensation includes a $600,000 annual salary, a 45% target bonus, and equity awards.
Key Highlights
- Dr. Diego Miralles resigned from the Board but was appointed President and Head of Research and Development.
- Thad Huston separated as Chief Financial Officer and principal financial and accounting officer, effective May 22, 2026.
- Mr. Huston will receive a cash payment of approximately $135,000 and up to nine months of COBRA.
- Dr. Fred Aslan resigned as President but remains CEO and Board member.
- Dr. Aslan was appointed principal financial officer and principal accounting officer.
- Dr. Miralles will receive an annual base salary of $600,000 and a target annual cash bonus of 45%.
- Dr. Miralles was granted options to purchase 232,500 shares and 77,500 restricted stock units.
Price Impact
More from ARTV